Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve Audited financial result for the quarter and financial year ended on 31st March, 2025 along with the Auditor''s Report and Certificate for unmodified opinion Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015

pdf

Shukra Pharmaceuticals Ltd.

27 Apr 2025

26.72

-1.94%

Corp. Note

Shukra Pharmaceuticals Ltd - 524632 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyShukra Pharmaceuticals Ltd 2CIN NO.L24231GJ1993PLC019079 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 2.66 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Mrs Arpita Kabra Designation: Company secretary and compliance officer EmailId: info@shukrapharmaceuticals.com Name of the Chief Financial Officer: Mrs Anar Jayesh Patel Designation: Chief Financial Officer EmailId: info@shukrapharmaceuticals.com Date: 27/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Shukra Pharmaceuticals Ltd.

05 Apr 2025

26.72

-1.94%

Company Update

Shukra Pharmaceuticals Ltd - 524632 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Compliance certificate under Reg. 74(5) of SEBI (DP) reg.2018 for the quarter ended 31.03.2025.

pdf

Shukra Pharmaceuticals Ltd.

29 Mar 2025

26.72

-1.94%

Company Update

Shukra Pharmaceuticals Ltd - 524632 - Intimation Of Change In Secretarial Auditor Of The Company

BSE India

Intimation of change in Secretarial Auditor of the company

pdf

Shukra Pharmaceuticals Ltd.

26 Mar 2025

26.72

-1.94%

Company Update

Shukra Pharmaceuticals Ltd - 524632 - Outcome Of Independent Directors Meeting Dated March 26, 2025.

BSE India

Outcome of the meeting of Independent directors held on today to consider the agendas as attached.

pdf

Shukra Pharmaceuticals Ltd.

26 Mar 2025

26.72

-1.94%

SAST

Shukra Pharmaceuticals Ltd - 524632 - Closure of Trading Window

BSE India

Intimation for Closure of Trading Window for the Quarter Ended on March 31, 2025.

pdf

Shukra Pharmaceuticals Ltd.

20 Mar 2025

26.72

-1.94%

Corp. Action

Shukra Pharmaceuticals Ltd - 524632 - Corporate Action-Updates on intimation of Sub division / Stock Split

BSE India

Intimation for notice received from BSE for new ISIN

pdf

Shukra Pharmaceuticals Ltd.

18 Mar 2025

26.72

-1.94%

Corp. Action

Shukra Pharmaceuticals Ltd - 524632 - Corporate Action-updates on Outcome of Sub division / Stock Split

BSE India

Submission of Activation letter received from the National Securities Depository Limited and Central Depository Services (India) Limited for stock split of shares.

pdf

Shukra Pharmaceuticals Ltd.

17 Mar 2025

26.72

-1.94%

Corp. Action

Shukra Pharmaceuticals Ltd - 524632 - Intimation Of New ISIN.

BSE India

Intimation of New ISIN for stock split for the record date 21st March, 2025.

pdf

Is Shukra Pharmaceuticals Ltd. worth buying?

54 Votes:

Buy 74.07%

Sell 14.81%

Hold 11.11%